FDA 483 - Exela Pharma Sciences LLC - November 15, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Exela Pharma Sciences LLC received a Form 483 citing numerous deficiencies across its drug manufacturing and 503B outsourcing facilities. Key issues include inadequate investigations into discrepancies and OOS results, failures in maintaining sterile conditions, and deficiencies in laboratory controls, data integrity, and equipment calibration. The firm also lacked proper stability data, personnel training for visual inspection, and compliant labeling for its outsourcing facility drug products.
ID · 60077e2a-4655-4ff7-84ff-713e02f8a6b0